<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "icsr-xml-v2.1.dtd">
<ichicsr lang="en">
    <ichicsrmessageheader>
        <messagetype>ichicsr</messagetype>
        <messageformatversion>2.1</messageformatversion>
        <messageformatrelease>2.0</messageformatrelease>
        <messagenumb>UCBPHAPROD-92321-320691</messagenumb>
        <messagesenderidentifier>UCBPVGPRD</messagesenderidentifier>
        <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
        <messagedateformat>204</messagedateformat>
        <messagedate>20130125162605</messagedate>
    </ichicsrmessageheader>
    <safetyreport>
        <safetyreportversion>2</safetyreportversion>
        <safetyreportid>CA-UCBSA-069937</safetyreportid>
        <primarysourcecountry>CA</primarysourcecountry>
        <occurcountry>CA</occurcountry>
        <transmissiondateformat>102</transmissiondateformat>
        <transmissiondate>20130125</transmissiondate>
        <reporttype>2</reporttype>
        <serious>1</serious>
        <seriousnessother>1</seriousnessother>
        <receivedateformat>102</receivedateformat>
        <receivedate>20121026</receivedate>
        <receiptdateformat>102</receiptdateformat>
        <receiptdate>20130116</receiptdate>
        <additionaldocument>2</additionaldocument>
        <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
        <companynumb>CA-UCBSA-069937</companynumb>
        <primarysource>
            <reportergivename>NANCY</reportergivename>
            <reporterfamilyname>BROCKEST</reporterfamilyname>
            <reportercountry>CA</reportercountry>
            <qualification>3</qualification>
            <studyname>#Solutions Program Canada Cimzia</studyname>
            <sponsorstudynumb>CERTOL01_Solutions Pr Canada</sponsorstudynumb>
            <observestudytype>3</observestudytype>
        </primarysource>
        <sender>
            <sendertype>1</sendertype>
            <senderorganization>UCB</senderorganization>
            <sendertitle>Dr.</sendertitle>
            <sendergivename>Peter</sendergivename>
            <senderfamilyname>Verdru</senderfamilyname>
            <senderstreetaddress>1950 Lake Park Drive</senderstreetaddress>
            <sendercity>Smyrna</sendercity>
            <senderstate>GA</senderstate>
            <senderpostcode>30080</senderpostcode>
            <sendercountrycode>US</sendercountrycode>
            <sendertel>9197673193</sendertel>
            <sendertelcountrycode>1</sendertelcountrycode>
            <senderfax>9197673174</senderfax>
            <senderfaxcountrycode>1</senderfaxcountrycode>
            <senderemailaddress>peter.verdru@ucb.com</senderemailaddress>
        </sender>
        <receiver>
            <receivertype>2</receivertype>
            <receiverorganization>FDA</receiverorganization>
            <receiverdepartment>Office of Surveillance and Epidemiology</receiverdepartment>
            <receivertitle>Mr.</receivertitle>
            <receivergivename>Roger</receivergivename>
            <receiverfamilyname>Goetsch</receiverfamilyname>
            <receiverstreetaddress>8201 Corporate Drive, Suite 540</receiverstreetaddress>
            <receivercity>Landover</receivercity>
            <receiverstate>MD</receiverstate>
            <receiverpostcode>20785</receiverpostcode>
            <receivercountrycode>US</receivercountrycode>
            <receivertel>3019189580</receivertel>
            <receivertelextension>194</receivertelextension>
            <receivertelcountrycode>1</receivertelcountrycode>
            <receiverfax>3019183134</receiverfax>
            <receiverfaxcountrycode>1</receiverfaxcountrycode>
            <receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
        </receiver>
        <patient>
            <patientinitial>MG</patientinitial>
            <patientbirthdateformat>102</patientbirthdateformat>
            <patientbirthdate>19390208</patientbirthdate>
            <patientonsetage>73</patientonsetage>
            <patientonsetageunit>801</patientonsetageunit>
            <patientweight>74.09</patientweight>
            <patientheight>167</patientheight>
            <patientsex>1</patientsex>
            <medicalhistoryepisode>
                <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
                <patientepisodename>Seronegative arthritis</patientepisodename>
                <patientmedicalcontinue>3</patientmedicalcontinue>
            </medicalhistoryepisode>
            <medicalhistoryepisode>
                <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
                <patientepisodename>Hypothyroidism</patientepisodename>
                <patientmedicalcontinue>3</patientmedicalcontinue>
            </medicalhistoryepisode>
            <medicalhistoryepisode>
                <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
                <patientepisodename>Nodal osteoarthritis</patientepisodename>
                <patientmedicalcontinue>3</patientmedicalcontinue>
            </medicalhistoryepisode>
            <medicalhistoryepisode>
                <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
                <patientepisodename>Nodal osteoarthritis</patientepisodename>
                <patientmedicalcontinue>3</patientmedicalcontinue>
            </medicalhistoryepisode>
            <medicalhistoryepisode>
                <patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
                <patientepisodename>Knee arthroplasty</patientepisodename>
                <patientmedicalstartdateformat>610</patientmedicalstartdateformat>
                <patientmedicalstartdate>200711</patientmedicalstartdate>
                <patientmedicalcontinue>3</patientmedicalcontinue>
            </medicalhistoryepisode>
            <patientpastdrugtherapy>
                <patientdrugname>ENBREL</patientdrugname>
                <patientdrugstartdateformat>610</patientdrugstartdateformat>
                <patientdrugstartdate>201106</patientdrugstartdate>
                <patientdrugenddateformat>610</patientdrugenddateformat>
                <patientdrugenddate>201205</patientdrugenddate>
            </patientpastdrugtherapy>
            <reaction>
                <primarysourcereaction>STAGE 1E DIFFUSE LARGE B-CELL LYMPHOMA </primarysourcereaction>
                <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
                <reactionmeddrallt>10012823</reactionmeddrallt>
                <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
                <reactionmeddrapt>10012823</reactionmeddrapt>
                <reactionstartdateformat>102</reactionstartdateformat>
                <reactionstartdate>20121023</reactionstartdate>
                <reactionfirsttime>165</reactionfirsttime>
                <reactionfirsttimeunit>804</reactionfirsttimeunit>
                <reactionoutcome>3</reactionoutcome>
            </reaction>
            <drug>
                <drugcharacterization>1</drugcharacterization>
                <medicinalproduct>CIMZIA</medicinalproduct>
                <drugauthorizationnumb>125,160</drugauthorizationnumb>
                <drugstructuredosagenumb>200</drugstructuredosagenumb>
                <drugstructuredosageunit>003</drugstructuredosageunit>
                <drugseparatedosagenumb>1</drugseparatedosagenumb>
                <drugintervaldosageunitnumb>2</drugintervaldosageunitnumb>
                <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
                <drugadministrationroute>058</drugadministrationroute>
                <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
                <drugindication>Rheumatoid arthritis</drugindication>
                <drugstartdateformat>102</drugstartdateformat>
                <drugstartdate>20120616</drugstartdate>
                <drugstartperiod>165</drugstartperiod>
                <drugstartperiodunit>804</drugstartperiodunit>
                <actiondrug>4</actiondrug>
                <activesubstance>
                    <activesubstancename>CERTOLIZUMAB PEGOL</activesubstancename>
                </activesubstance>
                <drugreactionrelatedness>
                    <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
                    <drugreactionasses>Diffuse large B-cell lymphoma stage I</drugreactionasses>
                    <drugassessmentsource>Company</drugassessmentsource>
                    <drugassessmentmethod>IN HOUSE SCALE</drugassessmentmethod>
                    <drugresult>RELATED</drugresult>
                </drugreactionrelatedness>
            </drug>
            <drug>
                <drugcharacterization>1</drugcharacterization>
                <medicinalproduct>CIMZIA</medicinalproduct>
                <drugauthorizationnumb>125,160</drugauthorizationnumb>
                <drugstructuredosagenumb>400</drugstructuredosagenumb>
                <drugstructuredosageunit>003</drugstructuredosageunit>
                <drugseparatedosagenumb>1</drugseparatedosagenumb>
                <drugintervaldosageunitnumb>2</drugintervaldosageunitnumb>
                <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
                <drugadministrationroute>058</drugadministrationroute>
                <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
                <drugindication>Rheumatoid arthritis</drugindication>
                <drugstartdateformat>102</drugstartdateformat>
                <drugstartdate>20120512</drugstartdate>
                <drugstartperiod>165</drugstartperiod>
                <drugstartperiodunit>804</drugstartperiodunit>
                <drugenddateformat>102</drugenddateformat>
                <drugenddate>20120602</drugenddate>
                <drugtreatmentduration>22</drugtreatmentduration>
                <drugtreatmentdurationunit>804</drugtreatmentdurationunit>
                <actiondrug>4</actiondrug>
                <activesubstance>
                    <activesubstancename>CERTOLIZUMAB PEGOL</activesubstancename>
                </activesubstance>
                <drugreactionrelatedness>
                    <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
                    <drugreactionasses>Diffuse large B-cell lymphoma stage I</drugreactionasses>
                    <drugassessmentsource>Company</drugassessmentsource>
                    <drugassessmentmethod>IN HOUSE SCALE</drugassessmentmethod>
                    <drugresult>RELATED</drugresult>
                </drugreactionrelatedness>
            </drug>
            <drug>
                <drugcharacterization>2</drugcharacterization>
                <medicinalproduct>FOLIC ACID</medicinalproduct>
                <drugstructuredosagenumb>1</drugstructuredosagenumb>
                <drugstructuredosageunit>003</drugstructuredosageunit>
                <drugseparatedosagenumb>1</drugseparatedosagenumb>
                <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
                <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
                <drugdosagetext>6/7</drugdosagetext>
                <drugadministrationroute>048</drugadministrationroute>
                <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
                <drugindication>Vitamin supplementation</drugindication>
                <drugstartdateformat>610</drugstartdateformat>
                <drugstartdate>200906</drugstartdate>
                <actiondrug>4</actiondrug>
                <activesubstance>
                    <activesubstancename>FOLIC ACID</activesubstancename>
                </activesubstance>
            </drug>
            <drug>
                <drugcharacterization>2</drugcharacterization>
                <medicinalproduct>METHOTREXATE</medicinalproduct>
                <drugstructuredosagenumb>25</drugstructuredosagenumb>
                <drugstructuredosageunit>003</drugstructuredosageunit>
                <drugseparatedosagenumb>1</drugseparatedosagenumb>
                <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
                <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
                <drugadministrationroute>058</drugadministrationroute>
                <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
                <drugindication>Rheumatoid arthritis</drugindication>
                <drugstartdateformat>610</drugstartdateformat>
                <drugstartdate>200906</drugstartdate>
                <actiondrug>4</actiondrug>
                <activesubstance>
                    <activesubstancename>METHOTREXATE</activesubstancename>
                </activesubstance>
            </drug>
            <drug>
                <drugcharacterization>2</drugcharacterization>
                <medicinalproduct>SYNTHROID</medicinalproduct>
                <drugstructuredosagenumb>150</drugstructuredosagenumb>
                <drugstructuredosageunit>004</drugstructuredosageunit>
                <drugseparatedosagenumb>1</drugseparatedosagenumb>
                <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
                <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
                <drugdosagetext>ONCE DAILY FOR 3 DAYS</drugdosagetext>
                <drugadministrationroute>048</drugadministrationroute>
                <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
                <drugindication>Hypothyroidism</drugindication>
                <actiondrug>4</actiondrug>
                <activesubstance>
                    <activesubstancename>LEVOTHYROXINE SODIUM</activesubstancename>
                </activesubstance>
            </drug>
            <drug>
                <drugcharacterization>2</drugcharacterization>
                <medicinalproduct>SYNTHROID</medicinalproduct>
                <drugstructuredosagenumb>175</drugstructuredosagenumb>
                <drugstructuredosageunit>004</drugstructuredosageunit>
                <drugseparatedosagenumb>1</drugseparatedosagenumb>
                <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
                <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
                <drugdosagetext>ONCE DAILY FOR 4 DAYS</drugdosagetext>
                <drugadministrationroute>048</drugadministrationroute>
                <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
                <drugindication>Hypothyroidism</drugindication>
                <actiondrug>4</actiondrug>
                <activesubstance>
                    <activesubstancename>LEVOTHYROXINE SODIUM</activesubstancename>
                </activesubstance>
            </drug>
            <drug>
                <drugcharacterization>2</drugcharacterization>
                <medicinalproduct>VITAMIN D</medicinalproduct>
                <drugstructuredosagenumb>1000</drugstructuredosagenumb>
                <drugstructuredosageunit>025</drugstructuredosageunit>
                <drugseparatedosagenumb>1</drugseparatedosagenumb>
                <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
                <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
                <drugadministrationroute>048</drugadministrationroute>
                <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
                <drugindication>Vitamin supplementation</drugindication>
                <actiondrug>4</actiondrug>
                <activesubstance>
                    <activesubstancename>ERGOCALCIFEROL</activesubstancename>
                </activesubstance>
            </drug>
            <summary>
                <narrativeincludeclinical>This non-interventional study report from Cimzia solution program was received by UCB (Affiliate ID: CAN_AE_2012_CZP_452) on 26-Oct-2012 from a registered nurse via medical representative. 

This case concerns a 73-year-old male subject from Canada with medical history of HLA B27 seronegative arthropathy, hypothyroidism, Heberden's nodes, Bouchard's nodes, and right total knee arthroplasty. The subject's past medications included Enbrel (etanercept). His concomitant medications included folic acid, methotrexate, Synthroid (levothyroxine sodium) and Vitamin D (ergocalciferol). 

The subject was initiated on Cimzia (certolizumab pegol) 400mg, subcutaneous, once every two weeks since 12-May-2012 for the treatment of rheumatoid arthritis in the trial "CERTOL01_Solutions Pr Canada for rheumatoid arthritis". From 16-Jun-2012, the dose of certolizumab pegol was 200 mg, subcutaneous, once every two weeks. 

The subject was seen by the physician and noted lesions on abdominal wall, under the skin, in the fat; however not in the abdominal cavity. The physician suspected possible sarcoma and/or lymphoma (onset date 23-Oct-2012; moderate in intensity). The physician performed ultrasound and biopsy and states that the tumor was inferior to the fat, 5 cm in diameter and protruding through belly. The physician stated that the tumor was fast growing as nothing was noted 3-4 weeks ago when the subject was last seen. The physician expected the biopsy results within 5 days.

At the time of report, the events were ongoing and therapy with certolizumab pegol was continued.

New relevant information was received by UCB on 16-Jan-2013 from the nurse. 

The patient's final diagnosis was 'stage 1E diffuse large B-cell lymphoma' (The previously reported events of suspected lymphoma and suspected sarcoma were replaced with the event 'stage 1E diffuse large B-cell lymphoma'). The patient is having follow-up at the hospital.</narrativeincludeclinical>
                <sendercomment>Elderly male subject with medical history of HLA B27 seronegative arthropathy and hypothyroidism experienced the event approximately 23 weeks after initiation of certolizumab pegol. The events had not resolved and therapy with certolizumab pegol was continued.</sendercomment>
            </summary>
        </patient>
    </safetyreport>
</ichicsr>